ClinicalTrials.gg
RecruitingNCT0590961814Updated Jul 22, 2025

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

A Phase 2 interventional study of Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO] and Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] in Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System and MGMT-Unmethylated Glioblastoma, sponsored by Sheba Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Sheba Medical Center · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing nivolumab in Glioblastoma — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Glioblastoma.

Planned enrollment
12th of 20
33 · median 36
Started
2023
the only one that year
Phase 2
12 of 20
2 open now
Primary completion
2028-07
later than 9 of 10 live
Registered
16th of 20
by date

Among the 20 studies testing nivolumab in Glioblastoma, this one is the 12th largest by planned enrollment, is the only one that started in 2023, is one of 12 in phase 2, reaches primary completion later than 9 of the 10 other live ones, and was the 16th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 20 studies testing nivolumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing nivolumab in Glioblastoma, or all of them as a file.
02

Study summary

A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB.

Subjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts:

Cohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy.

Cohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment.

Cohort 3: Patients with newly diagnosed GB who were evaluated for methylguanine-DNA methyltransferase(MGMT) methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.

Read the detailed description

A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB.

Subjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts:

Cohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy.

Cohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment.

Cohort 3: Patients with newly diagnosed GB who were evaluated for MGMT methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.

The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15) followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression evaluated by RECIST 1.1 and RANO criteria or intolerable toxicity. The subsequent 8 patients will receive crizanlizumab 5 miligram/kilogram (mg/kg) at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression. The subjects will continue the treatment until disease progression or until completion of 27 cycles (2 years). Subjects who complete 2 years of therapy will maintain follow-up.

Subjects in Cohort 3 will receive crizanlizumab starting from 4 weeks after completing radiation therapy. The first 2 subjects will receive crizanlizumab 2.5 mg/kg at C1D1 and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks. The subsequent 6 subjects will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by crizanlizumab every 4 weeks. Treatment will continue for up to 12 months or until disease progression or unacceptable toxicity.

Safety and tolerability will be assessed by CTCAE v 6.0 every week for the first 4 weeks followed by assessments every 2 weeks until Week 12, and then every 4 weeks.

Tumor response will be evaluated by brain Magnetic resonance imaging (MRI) every 8 weeks using RANO criteria. Patients with metastatic melanoma will also be evaluated with chest-abdomen and pelvis Computed tomography (CT) every 8 weeks for the evaluation of visceral disease using RECIST 1.1.

Patients with MBM (Cohort 1) whose primary tumor/non-brain tumor progresses on RECIST 1.1 but whose brain tumor/metastases show benefit (stable disease or better), may continue in the study at the investigator's discretion.

Quality of life will be assessed by the Quality of Life Questionnaire (EORTC QLQ-30) and Brain Neoplasm(QLQ BN-20) and by cognitive function tests.

Archived tissue samples (and optional fresh biopsy), CSF and blood samples will be drawn to assess pharmacokinetics and pharmacodynamics of the combined therapy and for collateral research aiming to define biomarkers for response.

03

Conditions studied

  • Advanced Glioblastoma
  • Metastatic Melanoma in the Central Nervous System
  • MGMT-Unmethylated Glioblastoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Cohort 1 (MBM) Inclusion Criteria

  1. Age ≥ 18 years.
  2. Estimated at least 3 months
  3. Have melanoma with primarily diagnosed or newly progressing .
  4. Was treated with 1 prior systemic line of immunotherapy - either inhibitor monotherapy or combined CTLA4 and PD-1 antibodies or another combination of immunotherapy. Patients with BRAF-mutant melanoma who have also received BRAF mutation targeted therapy are also eligible.
  5. Have failed prior immunotherapy line, either due to primary resistance or acquired resistance.
  6. Have defined by criteria and have at least one, non-previously irradiated brain metastasis of at least 1-cm short diameter. Otherwise, previously irradiated lesions should present with enlargement following radiation therapy.
  7. Is clinically stable with no neurological deficits. Patients may receive supportive therapy up to 10 mg of prednisone or the equivalent.
  8. Have (ECOG) performance status 0 or 1.
  9. Adequate organ function defined by blood tests for blood count and chemistry.
  10. Women of practicing an acceptable method of .
  11. Understand study procedures and willingness to comply for the entire duration of the study and to give written .

    Exclusion Criteria

  12. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 10 mg prednisone will be allowed
  13. Have .
  14. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.
  15. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.
  16. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.
  17. Previous or current brain hemorrhage.
  18. The patient had, or is expected to undergo, hematopoietic stem cell transplantation (HSCT).
  19. The patient had a for undergoing brain MRI.
  20. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  21. Pregnant or lactating
  22. Treatment with other investigational drugs within \<21 days of start of day 1 of the study treatment.
  23. Any contraindication for treatment with nivolumab according to the product's labels.

Cohort 2 (Recurrent or Progressive GB) Inclusion Criteria

  1. Age ≥ 18 years.
  2. Estimated life expectancy at least 3 months
  3. Have with recurrent or persistent GB
  4. Received therapy with brain irradiation and maintenance temozolamide.
  5. Measurable disease per RANO criteria on brain MRI.
  6. Have Eastern Cooperative Oncology Group (ECOG) performance status \<2.
  7. Adequate organ function defined by blood tests for blood count and chemistry.
  8. Women of childbearing potential practicing an acceptable method of birth control.
  9. Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.

Exclusion Criteria

  1. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed
  2. Have leptomeningeal spread.
  3. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.
  4. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.
  5. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.
  6. Previous or current brain hemorrhage.
  7. The patient had, or is expected to undergo, allogeneic HSCT.
  8. The patient had a contraindication for undergoing brain MRI.
  9. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  10. Pregnant or lactating
  11. Treatment with other investigational drugs within \<21 days of start of day 1 of the study treatment.
  12. Any contraindication for treatment with nivolumab according to the product's labels.

Cohort 3 (Newly Diagnosed Unmethylated GB) Inclusion Criteria

  1. Age ≥ 18 years.
  2. Estimated life expectancy at least 3 months.
  3. confirmed newly diagnosed GB.
  4. Tumor test result shows MGMT unmethylated type.
  5. Received definitive brain irradiation.
  6. Patients may be treated with novo TTF (optune) per local standard.
  7. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
  8. Adequate organ function defined by blood tests for blood count and chemistry.
  9. Women of childbearing potential practicing an acceptable method of birth control.
  10. Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent.

Exclusion Criteria

  1. Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed
  2. Have leptomeningeal spread.
  3. Previous life-threatening toxicity to anti-PD-1 antibody monotherapy.
  4. Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy.
  5. Previous exposure to Crizanlizumab or any other P-selectin inhibitor.
  6. Previous or current brain hemorrhage.
  7. The patient had, or is expected to undergo, allogeneic HSCT.
  8. The patient had a contraindication for undergoing brain MRI.
  9. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  10. Be pregnant or lactating
  11. Treatment with other investigational drugs within \<21 days of start of day 1 of the study treatment.

Any contraindication for treatment with nivolumab according to the product's labels

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Cohort 1 metastatic melanoma with brain metastases who failed immunotherapy

    The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression

  • Experimental
    Cohort 2 - Patients with recurrent or progressing GB following radiation and temozolamide.

    The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression

    Drug: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO] · Drug: Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]

  • Experimental
    Cohort 3: Patients with newly diagnosed GB

    crizanlizumab starting from 4 weeks after completing radiation therapy. The first 2 subjects will receive crizanlizumab 2.5 mg/kg at C1D1 and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks. The subsequent 6 subjects will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by crizanlizumab every 4 weeks. Treatment will continue for up to 12 months or until disease progression or unacceptable toxicity.

    Drug: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]

Interventions

  • DrugCrizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]

    Drug page: CrizanlizumabStudies of CrizanlizumabCrizanlizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5 mg/kg solution for injection

    Also known as: crizanlizumab

  • DrugNivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]

    Drug page: NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3 mg/mL solution for injection

    Also known as: nivolumab

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse, serious adverse events, immune-related AEs following treatment with crizanlizumab alone or in combination with nivolumab

    Safety and tolerability assessed by CTCAE v 6.0

    Time frame: 48 months

  2. The proportion of treatment discontinuation events related to the treatment combination

    Safety and tolerability assessed by CTCAE v 6.0

    Time frame: 48 months

Secondary outcomes

  1. Response Rate (RR) to crizanlizumab monotherapy and in combination with nivolumab

    evaluated by RECIST 1.1 and by RANO and RANO-BM criteria.

    Time frame: 48 months

  2. Progression-free survival (PFS) of patients with GB or MBM following treatment crizanlizumab monotherapy and in combination with nivolumab

    by brain MRI and CT of chest/abdomen and pelvis using RECIST 1.1 and RANO/RANO-BM criteria

    Time frame: evaluated every 8 weeks for 48 months

  3. Overall survival (OS) in patients with GB or MBM following treatment crizanlizumab monotherapy and in combination with nivolumab.

    Overall survival (OS) of the study population

    Time frame: 48 months

  4. Impact of the treatment protocol on health-related quality of life

    using EORTC questionnaires ,All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: evaluated every 6 weeks for 48 months

  5. Incidence of treatment-related adverse, serious adverse events, immune-related AEs of crizanlizumab maintenance therapy following whole-brain irradiation in patients with unmethylated GB

    evaluated by adverse events monitoring using CTCAE Version 6.0 and by documenting study treatment discontinuation and delays.

    Time frame: 48 months

  6. Disease control rate (DCR)

    valuated by rate of progression in patients with un-methylated GB treated with crizanlizumab maintenance therapy following whole-brain irradiation.

    Time frame: 48 months

Other outcomes

  1. The response to crizanlizumab monotherapy and in combination with nivolumab

    by iRANO criteria

    Time frame: 48 months

  2. Plasma levels of Crizanlizumab measurements

    Plasma levels of Crizanlizumab will be measured. The following parameters will be calculated: maximum (peak) plasma drug concentration (Cmax), area under the plasma concentration-time curve from time zero to time t (AUC0-t), area under the plasma concentration-time curve from time zero to infinity (AUC0-∞), mean residence time (MRT), elimination half-life (t½), elimination rate constant (Kel), apparent total body clearance of the drug from plasma (Cl), apparent volume of distribution (Vd). evaluated by blood for pharmacokinetics analyses that will be collected at the following time points: * Baseline (Day 1) prior to dosing and at 15 min, 30 min, 1 hour, 2 hours, 4 hours, and 8 ±1 hour post-dosing. * Day 2, at 20-24 hours post dosing. * Day 15±1 prior to dosing and at 15 min, 30 min, 1 hour, 2 hours, 4 hours, and 8 ±1 hour post-dosing.

    Time frame: during the first treatment cycle at the following time points: Baseline (Day 1),Day 2 and Day 15.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 60 months is close to that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
Jun 18, 2023
StartActual
Jul 11, 2023
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2030
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05909618
Collaborators
Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.
Responsible party
Dr. Ronnie Shapira (M.D, Head onco-gynecological service, Principal Investigator, Sheba Medical Center) — Principal investigator
First posted
Jun 18, 2023
Start date
Jul 11, 2023
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2030 (estimated)
Last update
Jul 22, 2025

Study contacts

Ronnie Shapira Frommer, Dr
Contact
ronnie.shapira@sheba.health.gov.il
972-3-5302243
Meital Bar
Contact
meital.bar@sheba.health.gov.il
972-3-5305201
Ronnie Shapira Frommer, Dr
principal investigator · Ronnie Shapira, MD Study Principal Investigator Ronnie.Shapira@sheba.health.gov.il

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Crizanlizumab · Nivolumab

Start the discussion